UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb DOI Creative Commons
Yanjing Guo, Xinyu Chen, Xiaowei Zhang

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Feb. 13, 2023

Ubiquitin-conjugating enzymes E2S (UBE2S) and E2C (UBE2C), which mediate the biological process of ubiquitination, have been widely reported in various cancers. Numb, cell fate determinant tumor suppressor, was also involved ubiquitination proteasomal degradation. However, interaction between UBE2S/UBE2C Numb their roles clinical outcome breast cancer (BC) are not elucidated. Oncomine, Cancer Cell Line Encyclopedia (CCLE), Human Protein Atlas (HPA) database, qRT-PCR, Western blot analyses were utilized to analyze expression types respective normal controls, tissues, lines. The UBE2S, UBE2C, BC patients with different ER, PR, HER2 status, grades, stages, survival status compared. By Kaplan-Meier plotter, we further evaluated prognostic value patients. We explored potential regulatory mechanisms underlying through overexpression knockdown experiments lines performed growth colony formation assays assess malignancy. In this study, showed that UBE2S UBE2C overexpressed while downregulated BC, higher grade, stage, poor survival. Compared hormone receptor negative (HR-) or HR+ demonstrated lower corresponding better increased reduced predicted prognosis patients, as well ER+ lines, decreased level enhanced malignancy, knocking down opposite effects. combination could potentially serve novel biomarkers for BC.

Language: Английский

Computer-aided diagnosis system combining FCN and Bi-LSTM model for efficient breast cancer detection from histopathological images DOI
Ümit Budak, Zafer Cömert, Zryan Najat Rashid

et al.

Applied Soft Computing, Journal Year: 2019, Volume and Issue: 85, P. 105765 - 105765

Published: Sept. 13, 2019

Language: Английский

Citations

140
Exosomes and exosomal RNAs in breast cancer: A status update DOI

S. Ayshwarya Lakshmi,

Thomas A. Hughes, Sulochana Priya

et al.

European Journal of Cancer, Journal Year: 2020, Volume and Issue: 144, P. 252 - 268

Published: Dec. 26, 2020

Language: Английский

Citations

123
PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? DOI
Gary A. Ulaner

American Journal of Roentgenology, Journal Year: 2019, Volume and Issue: 213(2), P. 254 - 265

Published: May 7, 2019

PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?Gary A. Ulaner1,2Audio Available | Share Claim CREDIT

Language: Английский

Citations

115
MicroRNA Shuttle from Cell-To-Cell by Exosomes and Its Impact in Cancer DOI Creative Commons
Heidi Schwarzenbach,

Peter B. Gahan

Non-Coding RNA, Journal Year: 2019, Volume and Issue: 5(1), P. 28 - 28

Published: March 21, 2019

The identification of exosomes, their link to multivesicular bodies and potential role as a messenger vehicle between cancer healthy cells opens up new approach the study intercellular signaling. Furthermore, fact that main cargo is likely be microRNAs (miRNAs) provides possibility transfer such molecules control activities in recipient cells. This review concerns brief overview biogenesis both exosomes miRNAs together with movement structures possible roles development progression breast, ovarian prostate cancers are discussed.

Language: Английский

Citations

99
Histological and molecular classification of breast cancer: what do we know? DOI Open Access
Renan Gomes do Nascimento, Kaléu Mormino Otoni

Mastology, Journal Year: 2020, Volume and Issue: 30

Published: Jan. 1, 2020

Breast cancer is the neoplasm most diagnosed malignancy and leading cause of mortality among women on a global scale. A profound increase in understanding clinical management breast has occurred over past two decades, which led to significant progress prevention, early detection, personalized therapy. However, biggest obstacle still faced practice complete intertumoral intratumoral heterogeneity, addition mechanisms multiple drug resistance systemic treatment disease. In view this, many studies focus analyzing morphological and, mainly, molecular patterns cancer, with purpose grouping these tumors into classes or entities assist management, elaboration epidemiological functional studies, performance trials. The common special histological types include: medullary carcinoma, metaplastic apocrine mucinous cribriform tubular neuroendocrine classic lobular pleomorphic non-specific type invasive ductal constitutes majority newly cases. As their aspect, intrinsic subtypes were identified based gene expression profiles. Today, four subgroups are widely reproduced well established routine, namely: Luminal A, B, HER2 +, Triple Negative. Thus, present article aims briefly address classification cancer.

Language: Английский

Citations

93
Computational Oncology in the Multi-Omics Era: State of the Art DOI Creative Commons
Guillermo de Anda‐Jáuregui, Enrique Hernández-Lemus

Frontiers in Oncology, Journal Year: 2020, Volume and Issue: 10

Published: April 7, 2020

Cancer is the quintessential complex disease. As technologies evolve faster each day, we are able to quantify different layers of biological elements that contribute emergence and development malignancies. In this multi-omics context, use integrative approaches mandatory in order gain further insights on oncological phenomena, move forward toward precision medicine paradigm. review, will focus computational oncology as an discipline incorporates knowledge from mathematical, physical, fields biomedical understanding cancer. We discuss current roles computation context multi-omic technologies, which include: data acquisition processing; management clinical research settings; classification, diagnosis, prognosis; models setting, including their for therapeutic target identification. machine learning network two most promising emerging paradigms, oncology. These provide a foundation how integrate description into coherent frameworks allow advances both basic settings.

Language: Английский

Citations

82
Molecular Classification of Breast Cancer: Relevance and Challenges DOI Open Access
Xinmin Zhang

Archives of Pathology & Laboratory Medicine, Journal Year: 2022, Volume and Issue: 147(1), P. 46 - 51

Published: Sept. 22, 2022

Appropriate patient management requires precise and meaningful tumor classification. Breast cancer classification continues to evolve from traditional morphologic evaluation more sophisticated systems with the integration of new knowledge research being translated into practice. is heterogeneous at molecular level, diversified patterns gene expression, which presumably responsible for difference in behavior prognosis. Since beginning this century, technology has been gradually applied breast on issues pertinent prognosis (prognostic signature) therapeutic prediction (predictive signature), much progress made.To summarize current state prospective future cancer.Sources include recent medical literature cancer.Identification intrinsic subtypes set a foundation refining Studies have explored genetic features within identified novel targets that led innovation clinical assays predict patient's provide specific guidelines decisions. With development implication these tools, we remarkably advanced our enhanced power optimal patients. However, challenges still exist. Besides accurate prognosis, are urgent need predictors response regimes. Further exploration along path will be critical improving

Language: Английский

Citations

44
Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems DOI Creative Commons

Huimin Shao,

Pegah Varamini

Cells, Journal Year: 2022, Volume and Issue: 11(3), P. 388 - 388

Published: Jan. 24, 2022

Bone is one of the most common metastatic sites among breast cancer (BC) patients. Once bone metastasis developed, patients’ survival and quality life will be significantly declined. At present, there are limited therapeutic options for BC patients with metastasis. Different nanotechnology-based delivery systems have been developed aiming to specifically deliver agents bone. The conjugation targeting nanoparticles can enhance selective various payloads lesion. current review highlights promising emerging advanced nanotechnologies designed targeted anticancer therapeutics, contrast agents, photodynamic photothermal materials achieve goal treatment, diagnosis, prevention A better understanding properties these new approaches may open up landscapes in medicine towards improving overall who experience

Language: Английский

Citations

40
Machine learning assisted analysis of breast cancer gene expression profiles reveals novel potential prognostic biomarkers for triple-negative breast cancer DOI Creative Commons

Anamika Thalor,

Hemant Kumar Joon,

Gagandeep Singh

et al.

Computational and Structural Biotechnology Journal, Journal Year: 2022, Volume and Issue: 20, P. 1618 - 1631

Published: Jan. 1, 2022

Tumor heterogeneity and the unclear metastasis mechanisms are leading cause for unavailability of effective targeted therapy Triple-negative breast cancer (TNBC), a (BrCa) subtype characterized by high mortality frequency distant cases. The identification prognostic biomarker can improve prognosis personalized treatment regimes. Herein, we collected gene expression datasets representing TNBC Non-TNBC BrCa. From complete dataset, subset reflecting solely known driver genes was also constructed. Recursive Feature Elimination (RFE) employed to identify top 20, 25, 30, 35, 40, 45, 50 signatures that differentiate from other BrCa subtypes. Five machine learning algorithms were on these selected features basis model performance evaluation, it found XGBoost performs best 25 20 genes, respectively. Out 45 two datasets, 34 be differentially regulated. Kaplan-Meier (KM) analysis Distant Metastasis Free Survival (DMFS) regulated revealed four out which novel could potential (POU2AF1 S100B). Finally, interactome pathway enrichment analyses carried investigate functional role identified in TNBC. These associated with MAPK, PI3-AkT, Wnt, TGF-β, signal transduction pathways, pivotal cascade. provide molecular-level insights into metastasis.

Language: Английский

Citations

39
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment DOI

Harshini Swaminathan,

K. Saravanamurali,

Sangilimuthu Alagar Yadav

et al.

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(8)

Published: July 14, 2023

Language: Английский

Citations

33